176 related articles for article (PubMed ID: 20130599)
21. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
[TBL] [Abstract][Full Text] [Related]
22. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
23. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
Beesley AH; Rampellini JL; Palmer ML; Heng JY; Samuels AL; Firth MJ; Ford J; Kees UR
Mol Cancer; 2010 Oct; 9():284. PubMed ID: 20979663
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
25. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
[TBL] [Abstract][Full Text] [Related]
26. Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK.
Liu Y; Ge J; Li Q; Gu L; Guo X; Ma ZG; Zhu YP
Neoplasma; 2013; 60(1):101-10. PubMed ID: 23067223
[TBL] [Abstract][Full Text] [Related]
27. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
[TBL] [Abstract][Full Text] [Related]
28. Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy.
Aljurf M; Nassar A; Saleh AJ; Almhareb F; Alzahrani H; Walter C; Bakr M; Ahmed SO; Chaudhri N
Hematol Oncol Stem Cell Ther; 2009; 2(3):399-402. PubMed ID: 20139053
[TBL] [Abstract][Full Text] [Related]
29. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood; 2012 Jan; 119(1):64-71. PubMed ID: 22025528
[TBL] [Abstract][Full Text] [Related]
30. A Novel t(4;11)(q21;q23) MLL-AF4 fusion transcript in infant leukemia.
Abdelhaleem M; Yi Q; Beimnet K; Grant R
Am J Hematol; 2007 Mar; 82(3):247. PubMed ID: 16924642
[No Abstract] [Full Text] [Related]
31. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.
Uckun FM; Herman-Hatten K; Crotty ML; Sensel MG; Sather HN; Tuel-Ahlgren L; Sarquis MB; Bostrom B; Nachman JB; Steinherz PG; Gaynon PS; Heerema N
Blood; 1998 Aug; 92(3):810-21. PubMed ID: 9680349
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
34. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
35. Infantile mixed phenotype acute leukemia (bilineal and biphenotypic) with t(10;11)(p12;q23);MLL-MLLT10.
Lou Z; Zhang CC; Tirado CA; Slone T; Zheng J; Zaremba CM; Oliver D; Chen W
Leuk Res; 2010 Aug; 34(8):1107-9. PubMed ID: 20299091
[TBL] [Abstract][Full Text] [Related]
36. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
37. NF-kappa B mediated up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia.
Zhang H; Zhu L; He H; Zhu S; Zhang W; Liu X; Zhao X; Gao C; Mei M; Bao S; Zheng H
Mol Cancer; 2014 Jan; 13():5. PubMed ID: 24393203
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
[TBL] [Abstract][Full Text] [Related]
39. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.
Robinson BW; Behling KC; Gupta M; Zhang AY; Moore JS; Bantly AD; Willman CL; Carroll AJ; Adamson PC; Barrett JS; Felix CA
Br J Haematol; 2008 Jun; 141(6):827-39. PubMed ID: 18422996
[TBL] [Abstract][Full Text] [Related]
40. Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.
Bennett CA; Winters AC; Barretto NN; Hemenway CS
Leuk Res; 2009 Jul; 33(7):937-47. PubMed ID: 19232721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
